Screener
Aura Biosciences, Inc. AURA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216808
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss before income taxes | (33,674) | (27,465) |
| Income tax provision, net | (11) | (18) |
| Net loss | $(33,685) | $(27,483) |
| Net loss per common share—basic and diluted | $(0.50) | $(0.55) |
| Weighted average common stock outstanding—basic and diluted | 67,447,576 | 50,126,148 |
| Comprehensive loss: | ||
| Net loss | $(33,685) | $(27,483) |
| Other comprehensive income (loss): |
Item 1. Financial Statements.
FAQ
- What is Aura Biosciences, Inc.'s EPS (diluted)?
- Aura Biosciences, Inc. (AURA) reported EPS (diluted) of -$0.50 in Q1 2026.
- How has Aura Biosciences, Inc.'s EPS (diluted) changed year-over-year?
- Aura Biosciences, Inc.'s EPS (diluted) increased by 9.1% year-over-year, from -$0.55 to -$0.50.
- What is the long-term trend for Aura Biosciences, Inc.'s EPS (diluted)?
- Over 3 years (2022 to 2025), Aura Biosciences, Inc.'s EPS (diluted) has grown at a -3.0% compound annual growth rate (CAGR), from -$1.96 to -$1.79.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Aura Biosciences, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude